Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy

Christophe Hézode1 Service d’Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, FranceCorrespondence[email protected]

Paul Kwo2 Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA

Jan Sperl3 Department of Hepatogastroenterology, Institut Klinické a Experimentální Medicíny (IKEM), Prague, Czech Republic

Peggy Hwang4 Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA

Jianmin Long4 Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA

Rohit Talwani4 Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA

Michael N Robertson4 Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA

Barbara A Haber4 Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA

show all

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date